Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TScan Therapeutics (TCRX) Change in Acquisitions & Divestments (2024 - 2025)

TScan Therapeutics (TCRX) has disclosed Change in Acquisitions & Divestments for 2 consecutive years, with $15.0 million as the latest value for Q4 2025.

  • Quarterly Change in Acquisitions & Divestments fell 80.14% to $15.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $201.2 million through Dec 2025, up 4.46% year-over-year, with the annual reading at $201.2 million for FY2025, 4.46% up from the prior year.
  • Change in Acquisitions & Divestments for Q4 2025 was $15.0 million at TScan Therapeutics, down from $34.0 million in the prior quarter.
  • The five-year high for Change in Acquisitions & Divestments was $76.2 million in Q2 2025, with the low at $15.0 million in Q4 2025.